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ABSTRACT: CAP37, a protein constitutively EXPRESSED in human neutrophils and induced in response 
to infection in corneal epithelial cells, plays a significant role in host defense against infection. Initially 
identified through its potent bactericidal activity for Gram-negative bacteria, it is now known that CAP37 
regulates numerous host cell functions, including corneal epithelial cell chemotaxis. Delineation of the 
domains of CAP37 that define these functions and synthesize bioactive peptides for therapeutic use have also 
been explored. Novel findings of a multifunctional domain between a 120 and 146 have also been reported. 
Here, in Biogenea Pharmaceuticals Ltd we for the first time generated a multifunctional peptide-mimic 
chemo-structure by connecting conserved fragments based on the neutrophil immune defense CAP37 protein 
as an in-silico antibacterial and wound-healing canditate agent. This in silico effort was accomplished by 
utilizing various generated descriptors of proteins, compounds and their interactions resulting in a 
performance/cost evaluation study for a GPU-based drug discovery application on volunteer computing 
approaches based on Automated Structure-Activity Relationship Minings in Connecting Chemical Structure 
to Biological Profiles for the generation of novel Computational biomodeling of 3D drug-protein binding free 
energy evaluation. 
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INTRODUCTION. 
The recent emergence of ‘extremely drug 
resistant’ bacterial pathogen strains is a major 
public health concern [1] exacerbated by the 
low number of newly approved drugs to treat 
bacterial infections [2–4] as the World Health 
Organization has warned that we are entering a 
“post-antibiotic era” where minor infections 
will be deadly [5], while US President Obama 
issued an Executive Order to combat 
antimicrobial resistance [6]. The 
Electronegativity Equalization Method (EEM) 
is a fast approach for charge calculation. A 
challenging part of the EEM is the 
parameterization, which is performed using ab 
initio charges obtained for a set of molecules. 
The goal of our work was to perform the EEM 
parameterization for selected sets of organic, 
organohalogen and organometal molecules. In 
previous studies it has been performed the most 
robust parameterization published so far. The 
EEM parameterization was based on 12 training 
sets selected from a database of predicted 3D 
structures (NCI DIS) and from a database of 
crystallographic structures (CSD). Each set 
contained from 2000 to 6000 molecules. It has 
also been shown that the number of molecules 
in the training set is very important for quality 
of the parameters. We have improved EEM 
parameters (STO-3G MPA charges) for 
elements that were already parameterized, 
specifically: C, O, N, H, S, F and Cl. The new 
parameters provide more accurate charges than 
those published previously. It has also been 
developed new parameters for elements that 
were not parameterized yet, specifically for Br, 
I, Fe and Zn. We have also performed crossover 
validation of all obtained parameters using all 
training sets that included relevant elements and 
confirmed that calculated parameters provide 
accurate charges [116]. The relatively recent 
recognition of the major role played by 
antimicrobial peptides (AMPs) in sustaining an 
effective host response to immune challenges 
was greatly in fl uenced by studies of amphibian 
peptides. AMPs are also widely regarded as a 
potential source of future antibiotics owing to a 
remarkable set of advantageous properties 
ranging from molecular simplicity to low-
resistance swift-kill of a broad range of 
microbial cells. However, the peptide formula 
per se, represents less than ideal drug 
candidates, namely because of poor 
bioavailability issues, potential 
immunogenicity, optional toxicity and high 
production costs. To address these issues, 
synthetic peptides have been designed, 
reproducing the critical peptide biophysical 
characteristic in unnatural sequence-specific 
oligomers. Thus, the use of peptidomimetics to 
overcome the limitations inherent to peptides 
physical characteristics is becoming an 
important and promising approach for 
improving the therapeutic potential of AMPs 
[104]. High-throughput screening (HTS) is one 
method being used to identify new drugs from 
large compound repositories [5]. In this regard, 
GlaxoSmithKline (GSK), has identified and 
released the activities and structures of a large 
set of anti-mycobacterials into the public 
domain; these are available in the ChEMBL 
database [6] (https://www.ebi.ac.uk/chembl/). 
This dataset consists of 776 anti-mycobacterial 
phenotypic hits with activity against M. bovis 
BCG. Since the early 1980s newly approved 
antibiotics, with the exception of six classes, 
have been analogues of previously released 
scaffolds [7] moreover the six new classes [8–
13] target Gram-positive pathogenic bacteria,
contributing to an urgent need to develop new
treatments aimed at infectious Gram-negative
bacteria, particularly those among the
“ESKAPE” pathogens [1] due to a shortage of
novel naturally-occurring antibiotics, efforts
have been made to design new antimicrobial
scaffolds with different modes of action [14–
18]. Amongst these, 177 compounds were
confirmed to be active against Mtb H37Rv
(MIC < 10 μM) and also displayed low human
cell-line toxicity. Oxidative folding of the
substrate converts on the neutrophil immune
defense CAP37 protein as an in-silico
antibacterial and wound-healing canditate  to
the inactive reduced form, which can then
interact with the periplasmic loop P2 of
transmembrane partner EcDsbB (Fig 1A) [32]
where the neutrophil immune defense CAP37
protein as an in-silico antibacterial and wound-
healing canditate -EcDsbB interaction
regenerates the oxidized state of the neutrophil
immune defense CAP37 protein as an in-silico
antibacterial and wound-healing canditate
interaction would block oxidation as a
neutrophil immune defense CAP37 protein as
an in-silico antibacterial and wound-healing
canditate  and thereby block oxidative folding
of virulence factors accordingly to the
phenotype of dsbA/dsbB null uropathogenic E.
coli (UPEC) cells is severe attenuation of
virulence in a mouse infection model, though
bacteria remain viable [35]. Similarly,
    ©The Author(s) 2016. This article is published with open access by the GSTF
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, June 2016
2
simulated mice model infected with a dsbA 
mutant of B. pseudomallei all survived whereas 
simulated mice model infected with wildtype all 
died [36]. 
Fig 1 
The DsbA-DsbB interaction. 
[1] Predicting pKa values of substituted phenols
from atomic charges: comparison of different
quantum mechanical methods and charge
distribution schemes [2]  predicting pKa values
from EEM atomic charges. [3]  Estimation of
pKa for organic oxyacids using calculated
atomic charges [5] predicting the pKa values for
aliphatic carboxylic acids and alcohols with
empirical atomic charge descriptors [6]
compared to different atomic charge schemes
for predicting pKa variations in substituted
anilines and phenols. [7] The use of atomic
charges and orbital energies as hydrogen-
bonding-donor parameters for QSAR studies in
comparison to MNDO, AM1 and PM3
methods. [8] Computational methods in
developing quantitative structure-activity
relationships (QSAR [9] generating quantum-
chemical descriptors in QSAR/QSPR studies
[10] utilizing as a handbook of molecular
descriptors [11] on charge indexes indicating
new topological descriptors [12] with
meaningful structural descriptors from charge
density. [13] Pharmacophores with historical
perspective and viewpoint from a medicinal
chemis [23] generated by conformer ensembles
using a multiobjective genetic algorithm. [24]
FLEXS: a method for fast flexible multi-
targeted peptide mimicking 
Neoligandsuperposition. [31] combined here
with a quantum theory of molecular structure
and its applications [32] on bonded-atom
fragments for describing molecular charge
densities. [45] Electronegativity equalization
method for the calculation of atomic charges in
molecules. [46] Bad bugs, no drugs: no
ESKAPE! An update from the Infectious
Diseases Society of America. Clinical 
infectious diseases: an official publication of the 
Infectious Diseases [23] DSB proteins and 
bacterial pathogenicity. [24] Disulfide Bond 
Formation System in Escherichia coli. [25] 
Structure and function of DsbA, a key bacterial 
oxidative folding catalyst. [41] Preparation and 
structure of the charge-transfer intermediate of 
the transmembrane redox catalyst DsbB. [42] 
Peptide Inhibitors of the Escherichia coli DsbA 
Oxidative Machinery Essential for Bacterial 
Virulence. [43]. Improved protein-multi-
targeted peptide mimicking Neoliganddocking 
using GOLD. The crystal structure of the On the 
neutrophil immune defense CAP37 protein as 
an in-silico antibacterial and wound-healing 
canditate -EcDsbB complex has been 
determined, through use of a covalent complex 
that trapped the otherwise transient interaction 
between the two proteins [39–41] where the 
structure revealed details of the intermolecular 
disulfide bond between On the neutrophil 
immune defense CAP37 protein as an in-silico 
antibacterial and wound-healing canditate  
Cys30 and EcDsbB Cys104, as well as a 
hydrogen bond between main chain atoms of 
On the neutrophil immune defense CAP37 
protein as an in-silico antibacterial and wound-
healing canditate  Arg148 (on the cisPro loop) 
and EcDsbB Phe106, and hydrophobic contacts 
between EcDsbB Pro100 and Phe101 and the 
On the neutrophil immune defense CAP37 
protein as an in-silico antibacterial and wound-
healing canditate  hydrophobic groove as an in-
silico antibacterial and wound-healing canditate 
with low micromolar affinity (Kd values 2–20 
μM), but they all required a cysteine for 
inhibition of the neutrophil immune defense 
CAP37 protein as an in-silico antibacterial and 
wound-healing canditate, suggesting that they 
targeted an active site cysteine in order to inhibit 
the enzyme [42]. Advances in integrative 
computational methodologies combined with 
chemical and genomics data offers a 
multifaceted in silico strategy for efficient 
selection and prioritization of potential new lead 
candidates in anti-TB drug discovery utilising 
chemical, biological and genomic databases 
enables the development and usage of 
computational ligand-based and structure-based 
tools in the discovery of TB targets linked to the 
MoA studies. Recently, chemogenomics, an 
approach that utilizes chemical space (physical 
and chemical properties) of small molecules and 
the genomic space defined by their targeted 
proteins to identify ligands for all targets and 
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vice versa [12], Structure Space and Historical 
Assay Space approaches have been used to 
determine the MoAs for the aforementioned 
published GSK phenotypic hits [13]. This 
initiative has paved the way to an array of 
computational target prediction approaches for 
TB. To date, 139 compounds were predicted to 
target proteins belonging to diverse biochemical 
pathways. In addition, TB mobile, [14] 
platforms has been used to predict targets for 
these phenotypic hits. Targets predicted from 
both methods include essential protein kinases 
and proteins in the folate pathway, as well as 
ABC transporters. Although, these methods 
provide valuable information on potential 
targets of anti-TB compounds identified in 
phenotypic screens, no in vitro validation of the 
in silico modeled targets has been so far 
reported. In the present work, we explored the 
importance of the various generated descriptors 
of proteins, compounds and their interactions 
resulting in a performance/cost evaluation study 
for a GPU-based drug discovery application on 
volunteer computing approaches based on 
Automated Structure-Activity Relationship 
Minings in Connecting Chemical Structure to 
Biological Profiles for the generation of novel 
Computational biomodeling of 3D drug-protein 
binding free energy evaluation by designing and 
developing small peptide-derived molecules 
predicted by computer modeling to bind to this 
region on the neutrophil immune defense 
CAP37 protein as an in-silico antibacterial and 
wound-healing canditate.  Our goal is to move 
from peptides to more ‘drug-like’ multi-
covalent pharmacophoric compounds, by 
designing and screening peptidomimetics 
residues resulting in silico hit and nine 
derivatives and their affinities and inhibitor 
potencies for the native discovery of the 
neutrophil immune defense CAP37 protein as 
an in-silico antibacterial and wound-healing 
canditate which were measured using a 
combination of differential scanning 
fluorimetry, isothermal titration calorimetry 
(ITC) and an enzyme prediction assays. The 
compounds were strong of high free energy 
binding inhibitors of the neutrophil immune 
defense CAP37 protein as an in-silico 
antibacterial and wound-healing canditate 
suggesting that additional binding virtual 
interactions will be required to generate 
significant inhibitor potency. 
Identification of bioactive  CAP37 motifs on 
virtual Docking based on CAP37 Petri nets. 
High throughput Virtual Docking experiments 
based on CAP37 Petri nets as a meta-node 
fragment-ligand were simulated on this 
scientific section for the efficient prediction 
analysis and for the High-dimension data 
profiling resulting in the generation of a 
multifunctional peptide-mimic chemo-structure 
based on a novel optimization algorithm for the 
structure prediction of multi-targeted peptide 
mimicking Neoligand binding sites as  an 
essential part of our in silico drug discovery 
process. A default value of 1 Å was 
incorporated for hydrogen bond donor and 
acceptor voxel grid clustering. The voxel is 
figured at the size of 1 Å × 1 Å × 1 Å, where 
only neighboring chemical driven voxels are 
included in a multi-pharmacophoric cluster on a 
larger residue distance parameter, in the range 
of 2.8 Å, resulting in the knowing of the 
location of the repeated conserved binding sites 
that greatly facilitates the meta-node visualized 
docking research for high free energy selected 
compounds hits, the scaffold lead optimization 
processes, the in silico design of multi-site-
directed chemogenomic targeted mutagenesis 
on Cytoscape simulated experiments where the 
hunt for structural chemical  features that 
influence the selectivity of binding pocket 
similarities in order to minimize the canditate's 
computer predicted adverse simulated effects. 
As part of this in silico computer-aided study it 
was found that pharmacophoric chemical 
docking total binding energy cutoffs alone can 
serve as the sole parameter to select neighboring 
binding grid voxels to define a metanode 
simulated genetic cluster by simply defining the 
cluster member distance parameters to 1 Å 
where only neighboring grid peptide targeted 
voxels define a given cluster indicating that the 
reverse small peptide docking is the rate-
limiting step for such drug predictions as an 
efficient pathway connected metanode 
algorithm for predicting multi-targeted peptide 
mimicking Neoligands with conserved binding 
sites to pharmacophore  hydrophobic features 
(APOLAR, AROM and ALIP).  
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MATERIALS AND METHODS 
  
 
Generation of a hyper-ligand utilizing a 
Sequential Solution for Index Dynamic 
Unified Theorem for Multiple Entities: 
The fragment ligand-based pathway free energy 
simulated in silico methods were here used 
streamline the CAP37 peptide-proteins linear 
repeated complexes for high throughput 
docking computer-aided calculations. The 
Internal Coordinate Mechanism (ICM) method 
was used to multiply selected chemical hits and 
generate conserved binding modes of the small 
fragment active molecules in the binding pocket 
sites of selected CAP37 protein domains in 
order to estimate the strength of the protein-
ligand free energy predictions based on the 
interactions as ICM scoring function: ΔG = 
ΔEIntFF + TΔSTor + α1ΔEHBond + 
α2ΔEHBDesol + α3ΔESolEl + α4ΔEHPhob + 
α5QSize where: ΔEIntFF is change in van der 
Waals interactions of multi-targeted ligand and 
protein-petide complex conserved targeted 
binding receptor and the internal force-field 
energy of the ligand, TΔSTor where the 
estimated change in free energy due to 
conformational entropy and weighted (α1 – α5), 
ΔEHPhob is the hydrophobic free energy gain, 
ΔEHBond is the hydrogen bond term, 
ΔEHBDesol accounts for the disruption of 
hydrogen bonds with solvent, ΔESolEl is the 
solvation electrostatic energy change upon 
binding, and Qsize is the ligand size correction 
term. The cluster of the softwares were used in 
our docking methods for these reverse cross-
docking studies generate 3D chemical 
structures which were generated and optimized 
by means such as:. 
and when m ≠ 1, then: 
Based on the percentile ranks reported in PDBe 
(http://www.ebi.ac.uk/pdbe-srv/view/entry), 
we selected CAP37 have better crystal structure 
quality compared to other structures. The 
coordinate files for 1ae5, 1a7s, 1fy1, 1fy3 
mutant of human heparin binding protein 
(CAP37) were retrieved and the ligand mol2 
and sdf coordinates were generated into 
separate different files. Using 
ICMiGEMDOCK-revesre in parallel docking 
peptide conserved receptor preparation 
computer assited tools the CAP37 protein 
structures were separately generated by 
removing all water molecules, add hydrogen, 
adding missing heavy atoms and hydrogen, and 
optimising amide groups and were generated as 
peptide-protein conserved linear ICM receptor 
binding targeted molecules. The “setup 
receptor” genetic clustering computer tool 
which was utilised to generate multiple receptor 
CPA37 common pathway sets of data maps 
with a grid size of 0.5Å where the six selected 
structure files were prepared and converted to 
ICM molecules for the generation of an 
APOLAR FragMap pharmacoscaffold feature 
by overlaping both AROM and ALIP FragMap 
features. An AROM|ALIP joint pharmacophore 
feature was generated on a “Refinement only” 
option from the preparation module utilized to 
prepare protein-peptide complexes based on 
Eqs. 1 and 2, in conjunction with Eq. 4 for the 
quantification of synergism (CI<1), additive 
simulated effect (CI=1), and antagonism (CI>1) 
[6,13,14], where at x% novel designed 
inhibition predicting properties where the 
general equation for two drugs is given below: 
Figure 1: CXXC motif (30CPHC33 in E. coli) forms 
the catalytic site [28] together with a cisPro loop 
and a groove formed from hydrophobic residues 
including Phe36, Phe174 and Tyr178.  
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The default grid box size settings of the top 
selected docked ligands performed in the 
AutoDock software was further optimized by a 
Cytoscape shortest simulated energy binding 
prediction on conserved pathways outputs to 
define the grids by centering them in the peptide 
common motif linear CAP37 crystal structures 
on the ligand representing a typical presentation 
of our similarity clustering consisting of 
druggable pharmacophores in algorithmic 
graphics of CI values for the prediction of the 
functioned simulated effect (fa) which  is 
illustrated in Figure 1 and  resulting in a Fa-CI 
plot also called Chou-Talalay plot as an ALIP 
pharmacophore feature. HBACC and NEG 
FragMap features where they are directly 
converted into respective HBACC and NEG 
pharmacophore features. The docking of the 
prepared ligands against the CAP37 proteins 
(code 1a7s, 1fy1, 1fy3 mutant of human heparin 
binding protein (CAP37) was carried out on a 
Fa-CI plot and isobologram generated another 
two conserved sides of the same coin, where Fa-
CI plot and its virtual docking  simulated effect 
was protein bacterial disease energy oriented 
and the isobologram generated was 
dosimetrically-oriented (Figure 1) indicating 
that the conversion of added hydrogen bond 
donor pharmacophore merged features is more 
complex and provide us with an “Extra 
precision” mode which was  used to perform the 
docking calculations to carry out the final 
fitness scoring and cross-docking rescoring of 
the energy-minimized binding poses from its 
druggable scoring function. 
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, June 2016
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Figure 2: Secondly, we have applied novel distinct 
potential target phanotypic ligand-based 
computational hit approaches in conjunction with a 
combined fragment structure-based peptide docking 
approach (parallel docking) to predict potential 
targets for an anti-CAP37 compound phenotypic hit 
series. To increase likely prediction docking 
accuracy we applied a virtual polygonogram based 
vistrual high through put tournament of distinct 
automated column methods, which are complement 
to each other representing for the first time an in vitro 
validation of these results for the predicted target-
compound interactions There are no drugs presently 
in clinical use that target this enzyme for Mtb, 
therefore this work provides experimentally 
confirmed ligands for mycobacterial DHFR, which 
will serve as starting points for further hit-to-lead 
optimisation. In addition, in our studies we thirdly 
presented rationall computational and experimental 
in silico drug discovery approaches that can 
effectively characterize and prioritize phenotypic 
assay hits. 
(5)
(6)
(4) 
=−logp(V|W,H)−logp(W|λ)−log(H|λ)−logp(λ) 
where nA is the conserved docked number of the 
merged pharmacophoric patches in the peptide-
protein binding pocket A complexes. N is the 
logical number of the redocked matching 
pharmacophoric ligand based predicted patch 
chemical pairs between the conserved CAP37 
bidning pocket A and the multi-targeted 
peptide mimicking Hyper NeoligandB. pdist is 
the median distance fitness score of two merged 
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, June 2016
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pharmacophoric patches as defined in Equation 
(5). mA,B contains the list of matched patch pairs 
from pockets A and multi-targeted peptide 
mimicking NeoligandB. The second term is the 
geodesic relative position difference averaged 
over all the matching patches: 
(10) Where G2 is the geodesic distance between 
the centers of the two patches.
The last term measures the size difference 
between the pocket A and multi-targeted 
peptide mimicking NeoligandB: 
Ed 
(11) here nA is the number of patches in the
protein pocket A and nB is the number of 
patches in the multi-targeted peptide mimicking 
NeoligandB. The three terms are linearly 
combined in Equation (8). 
Dataset collection and ligand estimation 
links on type probability stochastic CAP37 
protein block models. 
All dataset of peptide binding generated of short 
linear ligands or CAP37 protein generated 
decoys for a consensus target were harnessing 
on a stochastic propability CAP37 protein block 
model and top compound jits were extracted 
from the DUD database in mol2 format and 
were then in silico fragmented and converted 
into MOE database files where active 
pharmacophores were isolated from 
flouroquinolones, antibacterials known to 
inhibit DNA gyrase and topoisomerase IV 
[33,34] whose conserved short linear target-
ligand protein pairs were  in ChEMBL version 
17. 
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Figure 2: Then the active peptide mimicking 
pharmacophores were then merged and were re-
presented to a KNIME – DOCK cross-docking virtual 
screening model and SEA for further validation 
resulting in the generation of two fragment targeted 
shortest path length binding ligand-based method as 
correctly assigned on the corresponding merged 
gatifloxacin, ofloxacin, moxifloxacin and lexofloxacin 
pharmacophoric small fragments to Staphylococcus 
aureus topoisomerase IV (UniProt accession: 
P0C1U9) from the first top five docking predictions 
using SEA against the repeated topoisomerase IV 
motif regions which were found in position one and 
E-values ranged from 2.20E-46. In the second phase
for a more robust drug-peptide cross docking model
was applied where this model-independent multi-
targeted high total energy pepotide binding
chemical scaffold was generated by the merging of
three pharmacophores which were fragmented
from the moxifloxacin, lexofloxacin and ofloxacin
utilizing an overlapping observed retargeted drug
repositioning to the disease recored binding sites to
the correct known conserved target  in positions 1
and 2 for gatifloxacin isolated fragtments (Z-score =
6.35) and for the randomized fragments of the
moxifloxacin (Z-score = 7.99) respectively.
Ligand and structure-based target 
prediction simulation approaches on protein 
expression and purification experimental 
networks based on EEM parameterization. 
All fragmented and simularted peptide mimic 
ligand-based logical methods were used to 
enable the rational linear peprtide motif targeted 
prediction based solely on ligand 3D similarity 
properties in the presence of target structural 
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, June 2016
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information where multiple categories of naïve 
Bayesian classifiers (MCNBC) have been 
extensively performed in peptide target 
prediction docking and virtual screening studies 
[13], [22], [21]. A second distinct separate 
method compiling Similarity Ensemble 
Approach (SEA) which is widely used to 
predict common repeated targets based on 
chemical moiety similarities between a multi-
paharmacophoric compound of unknown MoA 
and of high free energy selected small ligands 
sets data with known through proximity applied 
targets [26] where each ORF was used to 
perform a BLAST peptide-protein fragment 
ligand based search against the CAP37 Protein 
Data Bank to determine which structure(s) will 
be used as template(s) to perform homology 
protein modelling of the ORFs or computed 
binding region domains. An in silico drug bank 
associated virtual screening based calculation of 
EEM parameter for High-dimension profiling 
peptide-protein pathway disease data modeling 
for connecting mimicking conserved ligand 
fragments based on the neutrophil immune 
defense CAP37 simulated effect was on 
Chemaxon, KNIME and Cytoscape platforms 
applied for the generation of an in-silico 
antibacterial and wound-healing canditate agent 
comprising all the merged 3D modelled 
structures within a set of structural properties 
which were rationally computed, including: i) 
the Druggability Score (DS) for each binding 
pocket, ii) the active binding domain site 
residues (if available) according to the data set 
residue template structures, iii) the conserved or 
family repeated motif linear relevant residues.  
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Figure 3: For each set of QM metanode predicted 
and simulates charges, the EEM parameterization 
annotated studies were performed at this scientific 
study and the generated in silico values of the 
parameters were provided as a general sketch of the 
KNIME-Chemaxon pipeline where all outputs, steps 
and chemical similarity summaries are available for 
download purpose and later analyses as a multi 
dimensional parameterization initial dataset 
construction. All CAP37 ORFs and possible peptide-
protein disease-drug interactions for all the strains 
of Cp were obtained by downloading the 
information available at the NCBI 
database(ftp://ftp.ncbi.nih.gov/genomes/Bacteria). 
To merge and rationally complement our shortest 
pathway driven fragment ligand-based methods, we 
also used a similarity based structure-peptide in 
silico approach for enabling the utility of our high 
free energy hit selected available structural 
information of a known target to identify small 
fragment like chemical compounds whose 3D 
molecular features are absent in well-defined 
ligands and are low ranked compounds by MCNBC 
and SEA. Hence, by merging the above mentioned 
selevted ligands on our high through put selected 
common targets identified from MCNBC-iGEMDOCK 
and SEA we utilized a structure-based drug discovery 
strategy involving docking improved calculations in 
parallele linking and pharmacophore merging the 
candidate compounds, in order to investigate their 
binding as defined by optimizing their binding site 
occupancy, orientation, non-covalent bond 
interactions and their ligand efficiency index (LEI). 
Exploring genomic space based on 2-D 
chemical space of ligands as an in silico 
CAP37 proximity prediction on ligand 
repositionings.  
All differential chemogenomic scanning ultra 
fluorimetry simulated biological experiments as 
advanced energy mapping prediction assays for 
the prediction of conserved fragments on the 
neutrophil immune defense CAP37 protein in-
silico associated antibacterial and wound-
healing canditate agent were simulated on 
chemical reactions of (25 mM HEPES pH 7.4, 
60 mM NaCl) which was ex vivo conditioned at 
a final reagnet concentration of 2.5 μM, in the 
presence of either 5.5% (v/v) DMSO 
(reference) or 2, 1,2, 0.8, 0.35, 0.725 or 0.0625 
mM of the test final compound (also in a final 
reagent concentration of 5% DMSO (v/v.)) 
enabling us adding further repositions of a 
meta-node or compound edge metadata plot 
analysis for the in silico visualization purposes, 
such as statistical free energy significance 
information analysis or perturbation magnitude 
similarity  regulations. The total final predicted 
number of the connecting conserved fragments 
based on the neutrophil immune defense 
CAP37 protein ligand as an in-silico 
antibacterial and wound-healing canditate 
multi-targeted ligands according to the 
computer-aided predictions by MCNBN, 
iGEMDock and SEA was 58 and 12 of these in 
silico screened chemical pharmacophoric 
compounds were amongst the top 200 
molecular formuals proposed by our ligand 
fragment based combinatorial structure-based 
approach (Fig. 1). Statistical results for the 
Knime-MetaMapp graphs are given in Figure 1 
revealing  zoom-ins that highlight the high 
refinement improved consrerved CAP37 
biochemical interpretability from coefficient 
Tanimoto chemical scaffold similarity analysis 
on Cytoscape  networks to KNIME-MetaMapp 
graphs where both SEA and docking screening 
approaches recognized short linear motif based 
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common pharmacophoric modulators by 
encouraging that our  poly-orthogonal 
chemogenomic prediction methods commonly 
identified eleven potential inhibitors for CAP37 
conserved binding domains (Fig. 1,). Out of 
these, six compounds, S4, S8, S6, S9, S12, (S1 
Table, supporting information) contain the 
1,3,9,6-tetrahydro-1,2,6benzoxy-propyl-
triazin-2-amine and the phenoxy-
benzocodenio-propoxyl chemical scaffolds, as 
two conserved pharmacophoric scaffolds on 
complete cytoscape session pathway files tion 
pharmacophoric informations into different 
edge clusters of cross-nodes using chemical 
similarity patterns on important binding pocket 
positions in CAP37 protein binding pocket by 
forming hydrophobic and hydrophilic of high 
free energy interactions with the molecular orbit 
residues. For instance, the above mentioned 
conserved moiety is known to further interact 
with Asp28 binding pocket as a residue 
important for the activation of the CAP37 
molecular structure where the merged 
pharmacophoric compounds S4, S12 and S9 
consist of novel multi-targeted CAP37 inhibitor 
scaffolds, which are the phenoxy-
benzocodenio-propoxyl methoxyisoquinolin-8-
yl, the substituted ,3,9,6-tetrahydro-
1,2,6benzoxy-propyl-triazin-2-aminequinoloin-
5-amine and the quinazoline-2,4, diamine
respectively. The combination of
chemogenomic biochemical reactant pair
mapping (red edges) and proximity chemical
scaffold  similarity (blue edges, Figure 1) into
one Cytoscape-KNIME based MetaMapp graph
correctly clustered the high free energy merged
pharmacophore residues into one group,
separate from the overlaps between MCNBC,
iGEMDock and SEA resulting into a consisted
of compound   About the 38% (8/21) of the
MCNBC predicted ligands were solely
suggested, and further merged into a dataset
where the SEA selected compounds had 29%
(5/17) and more than the 200 docking hits, 98%
(98/100) were exclusively proposed and merged 
their active pharmacophoric sites iinto a
annotated of hyperactivity data set resulting  in
a truly druggable metagraphic scaffold with a
comprehensive similarity manner of more than
200kcal/mol/A. We lastly aimed at merging the
280 unknown metabolprotein  signals in our
unique pharmacoscaffold where that could
structurally ligand based on identified chemical
small fragmented structures using the Fiehnlib
or NIST mass spectral libraries. Electron
ionization mass spectra of similar chemical
motif chemogenomic targeted structures are
known to cluster where a number of potential
CAP37 inhibitors of (Z-score = 8.14 and E-
value = 6.39E-15) where a LEI of 0.94 appear
in the top 100 set from cross-docking 
calculations since the LEIs are lower than 0.78. 
The single overlap between MCNBC and 
docking predictions is a hyper-mimic peptide 
like  compound S10 consisting of the 
methoxyphenyl substructure linked to a phenyl 
ring  identified by the multiple category naïve 
Bayesian classifier (MCNBC) using a similarity 
ensemble approach (SEA) and parallel  docking 
on protein-peptide domain calculations where 
the fragment active structure-based approach 
also identified potential ligands containing 
chemical druggable entities commonly found 
among bacterial inhibitors which could be 
merged into a  novel chemical features and has 
a molecular weight of 833.41.  
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Figure 4: A Cytoscape TCA simulated mass spectra 
of knowns merged fragment like pharmacophoric 
agents were mapped against all other multi-targetd 
compounds, bringing the shortest pathway associated 
unknown peptide based metabolites into proximity of 
druggable biochemically relevant cross docking of 
small ligand groups groups of metanodes in compiled 
antibacterial networks. Our newgly designed Hyper-
neoligandB is the highest fitness scoring of total 
binding energy merged compound, (S10) (LEI = 
3.41, Mwt = 517.86), 1-N-(4-triazol-
indomethoxyphenyl) purimidino-benzene-1,2-
diamine as a highly ranked potential CAP37 peptide 
inhibitor derived by in parallel docking of the 
compound 2-(2-phenoxyethoxy)-5-(thiophen-3-
yl)benzamide which were tested in in vitro 
experiments against M. bovis BCG. Cytoscape 
molecular mechanic simulated analysis  provide us 
the capability to further define one antibacterial 
CAP37 chemical similarity conserved  wound 
healing associated network as a host model or 
primary subsection molecular grid and further 
parameterized networks as additions free energy 
calculators  overall simulated experimental 
biochemical clarifications on merged scaffolds by 
adding knowns selected small fragment ligands using 
mass spectral similarity profiling data. We also used 
simulated proximity on other pathobiological 
antibacterial components targeted by drugs to define 
topological similarity trajectories between two 
pharmacophoric derived drugs and showed that the 
probability stochastic proximity increases the 
applicability of the existing drugs by performing at 
least as well as existing ligand based docking 
similarity-based approaches and multi-covered larger 
number of hyper drug multi-targeted diseases 
associations where all of the ORFs in the genome 
reference are highly conserved on human bacterial 
proteome., leading to a total of binding common 
region 2455 domains assignments from Pfam-A 
entries and 545 ORFs with a multicovalent domain 
assigned. Nevertheless, the recored drug like TCA 
peptide mimetic metabolites were still differential 
retained in a Monte Carlo sampling in close 
proximity, giving a data profiling optimization 
algorithm for the optimizarion of the biochemical 
relevance to polygonial-tiered MetaMapp 
antibacterial networks when aiming to increase the 
classification of the differentially sampling regulated 
metabolites of wellknown ligand structure into 
chemical trget template classes with potential 
biochemical modules.  
RESULTS 
This scientific article resulted in the 
identification of bioactive  CAP37 motifs on 
virtual Docking based on CAP37 Petri nets as 
shown in the Figure 1.utilising similarity 
proximity trajectories by providing novel 
shortest pathway driven insights into the 
druggable conserved pharmacophoric-peptide 
binding  mechanism of action, revealing more 
the top high ranked pathobiological ligand 
recovered components targeted by kown drugs 
and increases their merging applicability and 
interpretability into multi-targeted repurposing 
hyper drugs on metadata Monte Carlo sampling 
analysis of token drug game trajectories and 
quantum molecular modeling chemical 
    ©The Author(s) 2016. This article is published with open access by the GSTF
GSTF Journal of Advances in Medical Research (JAMR) Vol.1 No.4, June 2016
14
structures. The 10 peptidomimetic like binding 
compounds were virtually synthesized and 
cross-docked in differential scanning biological 
experimental fluorimetry dynamic simulation 
analysis for the rational designing short linear 
motif molecular ligand interaction repeated 
region networks describing gene regulation, 
signallings and whole-cell neutrophil immune 
defense. CAP37metabolism in hyper ligand 
simulated human cells for the generation of a 
hyper-ligand utilizing a Sequential Solution for 
Index Dynamic Unified Theorem for Multiple 
Entities as revealed in the (figure2) resulting in 
9 such putative common repeated bioactive 
peptide targets were identified 3 of them 
including 3-isopropylmalate dehydratase small 
aligned multi subpocket subunit on 50S 
ribosomal protein comprising anti-L30 and a 
Chromosomal replication hyper ligand optimal 
initiator against protein DnaA which have 
previously been reported in C. 
pseudotuberculosis [25,26]. While the other 6 
top druggable hit target peptide-ligand-protein 
complexes have been identified and reported in 
other pathogenic microorganisms, both in 
bacteria and parasites more low mass stochastic 
ligand based drug discovery based experimental 
simulations have to be performed from an initial 
state where there was one token on each similar 
gene clarification place and all other igemdock 
KNIME-PN metanodes token states 0, 
representing the conserved bacterial genotype 
of the defence system where mpore optimal 
generated biological free energy prediction 
simulations have to  be run for one arbitrary 
time unit to allow all transgenes to reach 
hyperligand cross docking basal expression 
antibacterial efficacy levels. Our novel 
multilevel algorithmic designed novel 
hyperligand permanently transactivated to 
virtually simulate merging pharmacophoric 
properties by compiling the selected FXR-
specific agonists and separate fragments of the 
known GW4064 compound which may play 
significant role for the designation of novel 
hyper molecules targeted on more conserved 
shortest pathways by incorporating  the 
remaining 26 druggable motif oriented targets 
that are not yet defined as ligand based putative 
targets for the generation of more molecular 
functionable, biological mimicking processes, 
in cellular compartmentalisations and bacterial 
drug discovery metabolic approache. Dataset 
collection and ligand estimation links on type 
probability stochastic CAP37 protein block 
models.were applied in this article as 
represented in the figure 3 for the quantitative 
measurements of quantum molecular mechanic 
stimulations of the molecular amount 
trajectories timecourses which have been 
generated for this metanode antibacterial 
biomodel analysis where qualitative biological 
CAP37 protein-petide experimental data on 
complexes responses to the free energy 
perturbation predictions as a common drug 
dsicveory situation in the literature based on this 
cross docking filter for the prediction of the 
number of selected merged pharmacophoric 
targets  to a final set of 13 multicovalent parallel 
targets. This in silico generated top ranking 
compound list was considered as mulit targeted 
druggable, essential data set comprising  long-
host homologous active bispecific target on 
human and bacterial proteins indicating a 
powerful feature of our cluster of genetic 
algorithms iindicating its capacity to utilize  the 
qualitative data to validate the profiling data 
and to refine  the reconstruct merged network 
qualitative models to find out whether some of 
these multi covalent energetically putative 
targets have already been reported in the drug 
bank literature or not. Ligand and structure-
based target prediction simulation approaches 
on protein expression and purification 
experimental networks based on EEM 
parameterization as represented in the (Figure 
4) were separately perfomed in this scientific
manuscriotwhere an otpimization and statistical
analysis of a general virtualized docking
biomodel of hyperligand binding energy
interactions against the conserved gene
expression short linear motif  elements based on
dynamic low mass stochastic multi-numeric
predicted drug discovery simulation of the
CAP37 mechanistic simulated homeostasis on a
simulated genotypoe-phenotype coverage
comparison trajectory analysis for genotype–
druggable relationship in our crystal chemical
structures by connecting conserved
pharmacophoric fragments based on the
neutrophil immune defense CAP37 protein-
petide complexesfor the generation of a hyper
molecule as an in-silico antibacterial and
wound-healing canditate agent More
mechanistic druggable simulated models in
non-reference bacterial strains based on  these
constructed models have to be developed  for
the optimization of our binding pockets
containing more profiling retained data for the
sampling of more regulated metabolite residues
from CSA database, for the fragmentation of the
list of 78 most effective druggable peptide-
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protein complexes  compared to the 
corresponding host druggable genome 
proteomes, leading to the generation oand to the 
identification of a macromolecule mimicking 
chemical structure  suitable to more 
antibacterial simulated model of the global 
metabolism. Exploring genomic space based on 
2-D chemical space of ligands as an in silico
CAP37 proximity prediction on ligand
repositionings were prepresented as  revealed in
the (Figure 5) where a simulated antibacterial
strain was used as a novel informatic in silico
drug discovery basis for the ligand based
structural chemical informatics study where for
each common targeted motif based element
sequence in this strain several models were built
using the following simulated virtual high-
dimension profiling data meta-cell fragment for
animal simulated calculated crystal drug
discovery comparison experiments as docking
visualization and  multi-numeric conserved
prediction homeostasis bacterial enzyme
screening assays on the generation of a
biological hypemimic multi-targeted
antibacterial molecule against the  neutrophil
immune defense CAP37 protein conserved
binding dokains based on EEM
parameterization selection of QM charges
induced by a novel peptide-mimic consensus
chemo-structure as an in-silico antibacterial and
wound-healing canditate agent. Finally, more
PSI-Blast conserved antibacterial strain model
research has to be restarted using the
aforementioned subpocket unit checkpoints
against more residue corresponding expressed
library templates by generating a template high
druggability score library consisted of all
conserved sequences from every individual
consensus pharmacophore binding peptide-
protein domains existed in the bacterial chain in
the Protein Data Bank (PDB).
CONCLUSIONS 
In this scientific work we generated a 
multifunctional peptide-mimic chemo-structure 
by connecting conserved fragments based on 
the neutrophil immune defense CAP37 protein 
as an in-silico antibacterial and wound-healing 
canditate agent. This in silico effort was 
accomplished by utilizing various generated 
descriptors of proteins, compounds and their 
interactions resulting in a performance/cost 
evaluation study for a GPU-based drug 
discovery application on volunteer computing 
approaches based on Automated Structure-
Activity Relationship Minings in Connecting 
Chemical Structure to Biological Profiles for 
the generation of novel Computational 
biomodeling of 3D drug-protein binding free 
energy evaluation. Take advantage the Monte 
Carlo samplings of token druggable predicted 
proximity predicted trajectories we modeled 
hype chemical structures by merging  more than 
of the 10 peptidomimetic pharmacophoric small 
molecule druggable compounds which were 
synthesized and computer asisited tested in 
differential virtual bacterial simulated models. 
More simulated scanning fluorimetry dynamic 
simulation approaches have to be performed 
resulting in more realistic simulated mass 
spectra analysis of knowns merged fragment-
like pharmacophoric agents for the optimum 
mapping of them  against all other multi-targetd 
compounds by bringing the shortest pathway 
associated unknown peptide based metabolites 
into proximity boundaries of druggable 
biochemically relevant analysis for designing 
motif molecular interaction networks 
describing gene regulation for the metagraphic 
signaling of the total whole-cell neutrophil 
immune defense CAP37metabolism in human 
cells. In the present work we have attempted to 
show a comprehensive consensus molecular 
study of the druggability cross docking firtness 
scoring analysis of a hyperligand molecule 
along the known completely short linear motif 
sequences on sikmulated bacterial  strains of C. 
pseudotuberculosis species profiming data to 
complement and strengthen further the 
annotated research work performed by our 
colleagues as a innovative multi-numeric 
simulated experimental biological simulated 
virtual drug and cell approach on animal trial 
experiments for the high dimensionally 
visualization and multi-numeric polygonial 
prediction on the generation of a hyper 
molecule comprising neutrophil immune 
defense CAP37 protein properties based on 
multi-scale EEM parameterization selected 
pathways of QM charges induced by a novel 
peptide-mimic chemo-structure for the 
discovery of an in-silico antibacterial and 
wound-healing canditate agent. After our 
pipeline was executed, a  top list of cross-
docked in parallel free energy estimkated on 
virtual bacterial strain highly druggable 
compounds were generated where the first 
hyper linked pharmacophore was consisted of 
18 ORFs-like acive fragments which were 
obtained from the fragmentation of the well 
known market drugs by resulting in these 
peptide motif ORFs that may had the unique 
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consensus druggable information about their 
antibacterial effect in the profiling set of the 
presents virulent strains. More defined 
topological similarity trajectories have to be 
generated between the generated pharmacophoric 
merged agents for the increase  of the probability 
stochastic proximity applicabilities of the existing 
drugs by performing at least as well as existing ligand 
based docking similarity-based approaches and 
multi-covered larger number of hyper drug multi-
targeted diseases associations where all of the ORFs 
in the genome reference are highly conserved on 
human bacterial proteome., leading to the generation 
of a more than 3000kcal/mol/A.  
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